Rare but high-severity drug toxicities such as allopurinol SCAR are hard to validate because no single center sees enough events, yet raw patient-level data sharing is often blocked by privacy, governance, and cross-border constraints. I hypothesize that federated validation using homomorphically encrypted pooled sufficient statistics will retain clinically useful calibration and discrimination for HLA-B*58:01- and CKD-aware allopurinol safety models while avoiding exchange of identifiable patient-level records.

Why this matters

• Allopurinol remains first-line therapy, but HLA-B*58:01 and CKD create nontrivial heterogeneity in catastrophic adverse-event risk.
• Rare-event pharmacogenomic safety work is exactly where decentralized validation is needed.
• Privacy-preserving analytics could make multi-site validation feasible without centralizing sensitive records.

Testable design

• Multicenter decentralized gout and autoimmune registry network.
• Each site computes encrypted sufficient statistics for predefined variables: HLA-B*58:01, eGFR category, starting dose, diuretic exposure, early systemic warning signs, and SCAR outcome.
• Central aggregator receives only encrypted statistics and estimates logistic or Bayesian rare-event models.
• Compare performance of privacy-preserving pooled estimation against conventional pooled analysis in a shadow dataset where lawful full-data pooling is possible.

Falsifiable predictions

1. Calibration slope difference between encrypted pooled estimation and conventional pooled analysis will be less than 0.05.
2. AUROC loss from privacy-preserving aggregation will be less than 0.02.
3. Cross-site participation will increase because governance barriers are lower than for raw data transfer.

Key limitations

• Very rare outcomes can still destabilize model estimation.
• Cryptographic overhead may limit turnaround time for iterative model development.
• Site-level phenotype harmonization remains a major non-cryptographic bottleneck.

References

1. Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 2005;102(11):4134-4139. DOI: 10.1073/pnas.0409500102
2. Hershfield MS, Callaghan JT, Tassaneeyakul W, et al. Clinical Pharmacogenetics Implementation Consortium guideline for human leukocyte antigen-B genotype and allopurinol dosing. Clin Pharmacol Ther. 2013;93(2):153-158. DOI: 10.1038/clpt.2012.209
3. Bos JW, Lauter K, Loftus J, Naehrig M. Improved security for a ring-based fully homomorphic encryption scheme. In: IMA Int Conf Cryptography and Coding. 2013:45-64. DOI: 10.1007/978-3-642-45239-0_4